AKT1 and non-small cell lung carcinoma: In addition, in NSCLC patients with PI3K/Akt pathway activation combined with epidermal growth factor receptor (EGFR) mutations, it was found that the combination of inhibitors of this pathway with EGFR Tyrosine Kinase Inhibitors (TKIs) improved the resistance of such patients to EGFR-TKIs (110).